Endo Plans Additional Oxymorphone IR Study
Endo is planning a short-term repeat-dose study of its oxymorphone IR tablets following a meeting with FDA about its pending NDA
Endo is planning a short-term repeat-dose study of its oxymorphone IR tablets following a meeting with FDA about its pending NDA